Neurocrine Biosciences (NBIX) 18.92 $NBIX
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed Nov 12, 12:56PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.
NBIX: 18.92 (-0.22)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 11.9% (NBIX)
Comtex SmarTrend(R) - Tue Nov 11, 10:03AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 weeks, Neurocrine Biosciences has returned 11.91% as of today's recent price of $18.89.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Looking Forward To A Big Year
Stephen Simpson, CFA - at Seeking Alpha - Thu Nov 06, 10:57AM CST
NBIX: 18.92 (-0.22), ABBV: 64.00 (+0.37)
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:09PM CST
NBIX: 18.92 (-0.22)
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
PR Newswire - Mon Nov 03, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston.
NBIX: 18.92 (-0.22)
Neurocrine meets 3Q profit forecasts
Automated Insights - Mon Nov 03, 5:00PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a third-quarter loss of $15.9 million.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences EPS in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:04PM CST
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Reports Third Quarter 2014 Results
PR Newswire - Mon Nov 03, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or $0.21 loss per share, compared to a net loss of $11.1 million, or $0.17 loss per share, for the same period in 2013. For the nine months ended September 30, 2014, the Company reported a net loss of $41.1 million, or $0.56 loss per share, as compared to net loss of $35.4 million, or $0.53 loss per share, for the first three quarters of last year.
NBIX: 18.92 (-0.22)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:35PM CST
RKT: 55.60 (-0.27), HLF: 38.50 (+0.65), EGAN: 5.19 (-0.19), CUTR: 10.53 (+0.19), DXPE: 65.54 (-1.19), AEIS: 20.64 (+0.11), NOR: 3.90 (-0.06), KBR: 18.85 (+0.12), SGY: 22.90 (+1.04), RTEC: 9.16 (+0.07), PKT: 7.10 (+0.05), OGS: 38.13 (+0.15), BKH: 53.89 (-0.53), KAMN: 40.86 (-0.27), EOX: 2.76 (+0.06), MR: 31.06 (-0.16), RKUS: 12.32 (+0.23), LCI: 46.88 (-1.40), NBIX: 18.92 (-0.22), PQ: 4.12 (+0.17), RBC: 71.12 (-0.03), CHGG: 6.90 (+0.04), AIG: 53.90 (-0.60), MRO: 32.36 (+0.41), GRT: 13.84 (-0.02), EPAM: 49.64 (+0.47), CKP: 12.70 (-0.14), SBRA: 27.12 (-0.53), MDU: 25.09 (+0.09), NTRI: 18.36 (-0.14), ELNK: 4.22 (+0.04), EQC: 25.60 (-0.33), CVD: 100.30 (-0.23), IART: 47.64 (-0.47), FN: 17.81 (+0.31), APL: 33.13 (+0.13), BDE: 8.81 (-0.09), AGU: 100.28 (+0.52), PLOW: 23.18 (+0.22), REG: 60.74 (-0.70), QLYS: 36.63 (+0.96), GALE: 1.87 (-0.01), ANV: 1.37 (+0.17), ININ: 47.97 (+1.02), FTR: 6.81 (+0.08), GTY: 18.25 (-0.17), MCEP: 16.17 (-0.64), CYH: 45.11 (-1.09), SKH: 7.10 (+0.05), ACXM: 18.57 (+0.04), PL: 69.70 (-0.18), RLD: 11.52 (-0.03), CXW: 36.00 (-0.15), SALE: 15.03 (+0.34), ENH: 57.67 (-0.10), CRK: 11.81 (+0.44), AMTG: 16.26 (+0.05), OTTR: 29.17 (-0.22), NLS: 14.53 (+0.25)
Neurocrine Biosciences awarded US FDA's Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
M2 - Fri Oct 31, 11:58AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in treating tardive dyskinesia.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
PR Newswire - Thu Oct 30, 6:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. The breakthrough designation also allows intensive discussions with the FDA which are intended to expedite the development and review process of eligible drugs.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 3:05PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, November 3, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 18.92 (-0.22)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 13.21 (-0.54), BCRX: 10.07 (-0.32), NBIX: 18.92 (-0.22), ONTY: 1.70 (+0.02), DYAX: 12.83 (-0.51)
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
PR Newswire - Mon Oct 20, 3:05PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double-blind, placebo-controlled trial of approximately 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective disorder. The initial six weeks of treatment consists of an efficacy and safety assessment of 80mg and 40mg once-daily NBI-98854 against placebo. This is followed by an additional 46 weeks of long-term safety assessment where all subjects are randomized in a blinded fashion to either 80mg or 40mg once-daily NBI-98854. Topline efficacy data is expected in the second half of 2015.
NBIX: 18.92 (-0.22)
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies
BMD Asset Management and Research - at Seeking Alpha - Mon Oct 20, 6:40AM CDT
JNJ: 108.16 (-0.91), NBIX: 18.92 (-0.22), GILD: 102.06 (-2.14), ALXN: 188.76 (-4.83), ABBV: 64.00 (+0.37), ENTA: 44.24 (+1.02), CELG: 104.05 (-3.38)
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
PR Newswire - Thu Oct 02, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences elects Malcolm Lloyd-Smith as chief regulatory officer
M2 - Thu Oct 02, 6:33AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the appointment of Malcolm Lloyd-Smith as its chief regulatory officer.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
PR Newswire - Wed Oct 01, 4:20PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed Nov 12, 12:56PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.
NBIX: 18.92 (-0.22)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 11.9% (NBIX)
Comtex SmarTrend(R) - Tue Nov 11, 10:03AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 weeks, Neurocrine Biosciences has returned 11.91% as of today's recent price of $18.89.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Looking Forward To A Big Year
Stephen Simpson, CFA - at Seeking Alpha - Thu Nov 06, 10:57AM CST
NBIX: 18.92 (-0.22), ABBV: 64.00 (+0.37)
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:09PM CST
NBIX: 18.92 (-0.22)
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
PR Newswire - Mon Nov 03, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston.
NBIX: 18.92 (-0.22)
Neurocrine meets 3Q profit forecasts
Automated Insights - Mon Nov 03, 5:00PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a third-quarter loss of $15.9 million.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences EPS in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:04PM CST
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Reports Third Quarter 2014 Results
PR Newswire - Mon Nov 03, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or $0.21 loss per share, compared to a net loss of $11.1 million, or $0.17 loss per share, for the same period in 2013. For the nine months ended September 30, 2014, the Company reported a net loss of $41.1 million, or $0.56 loss per share, as compared to net loss of $35.4 million, or $0.53 loss per share, for the first three quarters of last year.
NBIX: 18.92 (-0.22)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:35PM CST
RKT: 55.60 (-0.27), HLF: 38.50 (+0.65), EGAN: 5.19 (-0.19), CUTR: 10.53 (+0.19), DXPE: 65.54 (-1.19), AEIS: 20.64 (+0.11), NOR: 3.90 (-0.06), KBR: 18.85 (+0.12), SGY: 22.90 (+1.04), RTEC: 9.16 (+0.07), PKT: 7.10 (+0.05), OGS: 38.13 (+0.15), BKH: 53.89 (-0.53), KAMN: 40.86 (-0.27), EOX: 2.76 (+0.06), MR: 31.06 (-0.16), RKUS: 12.32 (+0.23), LCI: 46.88 (-1.40), NBIX: 18.92 (-0.22), PQ: 4.12 (+0.17), RBC: 71.12 (-0.03), CHGG: 6.90 (+0.04), AIG: 53.90 (-0.60), MRO: 32.36 (+0.41), GRT: 13.84 (-0.02), EPAM: 49.64 (+0.47), CKP: 12.70 (-0.14), SBRA: 27.12 (-0.53), MDU: 25.09 (+0.09), NTRI: 18.36 (-0.14), ELNK: 4.22 (+0.04), EQC: 25.60 (-0.33), CVD: 100.30 (-0.23), IART: 47.64 (-0.47), FN: 17.81 (+0.31), APL: 33.13 (+0.13), BDE: 8.81 (-0.09), AGU: 100.28 (+0.52), PLOW: 23.18 (+0.22), REG: 60.74 (-0.70), QLYS: 36.63 (+0.96), GALE: 1.87 (-0.01), ANV: 1.37 (+0.17), ININ: 47.97 (+1.02), FTR: 6.81 (+0.08), GTY: 18.25 (-0.17), MCEP: 16.17 (-0.64), CYH: 45.11 (-1.09), SKH: 7.10 (+0.05), ACXM: 18.57 (+0.04), PL: 69.70 (-0.18), RLD: 11.52 (-0.03), CXW: 36.00 (-0.15), SALE: 15.03 (+0.34), ENH: 57.67 (-0.10), CRK: 11.81 (+0.44), AMTG: 16.26 (+0.05), OTTR: 29.17 (-0.22), NLS: 14.53 (+0.25)
Neurocrine Biosciences awarded US FDA's Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
M2 - Fri Oct 31, 11:58AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in treating tardive dyskinesia.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
PR Newswire - Thu Oct 30, 6:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. The breakthrough designation also allows intensive discussions with the FDA which are intended to expedite the development and review process of eligible drugs.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 3:05PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, November 3, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 18.92 (-0.22)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 13.21 (-0.54), BCRX: 10.07 (-0.32), NBIX: 18.92 (-0.22), ONTY: 1.70 (+0.02), DYAX: 12.83 (-0.51)
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
PR Newswire - Mon Oct 20, 3:05PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double-blind, placebo-controlled trial of approximately 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective disorder. The initial six weeks of treatment consists of an efficacy and safety assessment of 80mg and 40mg once-daily NBI-98854 against placebo. This is followed by an additional 46 weeks of long-term safety assessment where all subjects are randomized in a blinded fashion to either 80mg or 40mg once-daily NBI-98854. Topline efficacy data is expected in the second half of 2015.
NBIX: 18.92 (-0.22)
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies
BMD Asset Management and Research - at Seeking Alpha - Mon Oct 20, 6:40AM CDT
JNJ: 108.16 (-0.91), NBIX: 18.92 (-0.22), GILD: 102.06 (-2.14), ALXN: 188.76 (-4.83), ABBV: 64.00 (+0.37), ENTA: 44.24 (+1.02), CELG: 104.05 (-3.38)
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
PR Newswire - Thu Oct 02, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences elects Malcolm Lloyd-Smith as chief regulatory officer
M2 - Thu Oct 02, 6:33AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the appointment of Malcolm Lloyd-Smith as its chief regulatory officer.
NBIX: 18.92 (-0.22)
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
PR Newswire - Wed Oct 01, 4:20PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer.
NBIX: 18.92 (-0.22)
